Skip to main content
Erschienen in: Tumor Biology 8/2014

01.08.2014 | Research Article

Expression of CD34 and Maspin in ameloblastoma from a West African subpopulation

verfasst von: S. E. Udeabor, A. O. Adisa, B. Kolude, M. Barbeck, C. J. Kirkpatrick, R. A. Sader, S. Ghanaati

Erschienen in: Tumor Biology | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Ameloblastoma is a locally invasive odontogenic tumor with a high recurrence rate. Its local invasiveness is aided by angiogenesis, which can be correctly estimated by CD34. On the other hand, maspin decreases the local invasive and metastatic capability of cancer cells and functions as an angiogenesis inhibitor. We aim to assess the association between maspin expression and microvessel density in ameloblastoma. Twenty-five formalin-fixed paraffin-embedded (FFPE) blocks of ameloblastoma cases were prepared for antibody processing to CD34 and maspin. Positive immunohistochemical staining was marked by brown cytoplasmic/membrane coloration for CD34 and by nuclear/cytoplasmic coloration for maspin. At the ×40 magnification, we counted blood vessels in two areas of dimension; 300 × 400 μm (area A) and 150 × 200 μm (area B) adjacent to the tumor region to assess relative dispersion of the vessels bordering the tumor. The overall approximate microvessel density (MVD) for area A = 11 (minimum 2, maximum 21) and that for area B = 5 (minimum 1, maximum 10). The MVD in the area A of plexiform ameloblastoma was similar to that of the unicystic, while the hemangiomatous variant had the highest MVD for area A. Maspin positivity was present only in the cytoplasm of ameloblast, stellate reticulum, and the fibrous connective tissue in varying proportions. There was no evidence of the anti-angiogenesis effect of maspin in ameloblastoma from this study. The significance of cytoplasmic localization of maspin in the ameloblasts and stellate reticulum cells needs further investigation.
Literatur
1.
Zurück zum Zitat Jordan RCK, Speight PM. Current concepts of odontogenic tumours. Diagn Histopathol. 2009;15(6):303–10.CrossRef Jordan RCK, Speight PM. Current concepts of odontogenic tumours. Diagn Histopathol. 2009;15(6):303–10.CrossRef
2.
3.
Zurück zum Zitat Kumamoto H, Ohki K, Ooya K. Association between vascular endothelial growth factor (VEGF) expression and tumor angiogenesis in ameloblastomas. J Oral Pathol Med. 2002;31:28–34.PubMedCrossRef Kumamoto H, Ohki K, Ooya K. Association between vascular endothelial growth factor (VEGF) expression and tumor angiogenesis in ameloblastomas. J Oral Pathol Med. 2002;31:28–34.PubMedCrossRef
4.
Zurück zum Zitat Nagatsuka H, Hibi K, Gunduz M, Tsujigiwa H, Tamamura R, Sugahara T, et al. Various immunostaining patterns of CD31, CD34 and endoglin and their relationship with lymph node metastasis in oral squamous cell carcinomas. J Oral Pathol Med. 2005;34:70–6.PubMedCrossRef Nagatsuka H, Hibi K, Gunduz M, Tsujigiwa H, Tamamura R, Sugahara T, et al. Various immunostaining patterns of CD31, CD34 and endoglin and their relationship with lymph node metastasis in oral squamous cell carcinomas. J Oral Pathol Med. 2005;34:70–6.PubMedCrossRef
5.
Zurück zum Zitat Lanza F, Healy L, Sutherland DR. Structural and functional features of the CD34 antigen: an update. J Biol Regul Homeost Agents. 2001;15:1–13.PubMed Lanza F, Healy L, Sutherland DR. Structural and functional features of the CD34 antigen: an update. J Biol Regul Homeost Agents. 2001;15:1–13.PubMed
6.
Zurück zum Zitat Seifi S, Shafaie S, Ghadiri S. Microvessel density in follicular cysts, keratocystic odontogenic tumours and ameloblastomas. Asian Pacific J Cancer Prev. 2011;12:351–6. Seifi S, Shafaie S, Ghadiri S. Microvessel density in follicular cysts, keratocystic odontogenic tumours and ameloblastomas. Asian Pacific J Cancer Prev. 2011;12:351–6.
7.
Zurück zum Zitat Sager R, Sheng S, Pemberton P, Hendrix MJ. Maspin. A tumor suppressing serpin. Adv Exp Med Biol. 1997;425:77–88.PubMedCrossRef Sager R, Sheng S, Pemberton P, Hendrix MJ. Maspin. A tumor suppressing serpin. Adv Exp Med Biol. 1997;425:77–88.PubMedCrossRef
8.
Zurück zum Zitat Lockett J, Yin S, Li X, Meng Y, Sheng S. Tumor suppressive maspin and epithelial homeostasis. J Cell Biochem. 2006;97(4):651–60.PubMedCrossRef Lockett J, Yin S, Li X, Meng Y, Sheng S. Tumor suppressive maspin and epithelial homeostasis. J Cell Biochem. 2006;97(4):651–60.PubMedCrossRef
9.
Zurück zum Zitat Goulet B, Chan G, Chambers AF, Lewis JD. An emerging role for the nuclear localization of maspin in the suppression of tumor progression and metastasis. Biochem Cell Biol. 2012;90(1):22–38.PubMed Goulet B, Chan G, Chambers AF, Lewis JD. An emerging role for the nuclear localization of maspin in the suppression of tumor progression and metastasis. Biochem Cell Biol. 2012;90(1):22–38.PubMed
10.
Zurück zum Zitat Ghanaati S, Barbeck M, Lorenz J, Stuebinger S, Seitz O, Landes C, et al. Synthetic bone substitute material comparable with xenogeneic material for bone tissue regeneration in oral cancer patients: first and preliminary histological, histomorphometrical and clinical results. Ann Maxillofac Surg. 2013;3(2):126–38.PubMedCentralPubMedCrossRef Ghanaati S, Barbeck M, Lorenz J, Stuebinger S, Seitz O, Landes C, et al. Synthetic bone substitute material comparable with xenogeneic material for bone tissue regeneration in oral cancer patients: first and preliminary histological, histomorphometrical and clinical results. Ann Maxillofac Surg. 2013;3(2):126–38.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Dunstan S, Powe DG, Wilkinson M, et al. The stroma of oral squamous cell carcinomas show increased vascularity compared with adjacent host tissue. Br J Cancer. 1997;75:559–65.PubMedCentralPubMedCrossRef Dunstan S, Powe DG, Wilkinson M, et al. The stroma of oral squamous cell carcinomas show increased vascularity compared with adjacent host tissue. Br J Cancer. 1997;75:559–65.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Guzmán-Medrano R, Arreola-Rosales RL, Shibayama M, Silva-Olivares DA, Bologna-Molina R, Rodríguez MA. Tumor-associated macrophages and angiogenesis: a statistical correlation that could reflect a critical relationship in ameloblastoma. Pathol Res Pract. 2012;208(11):672–6.PubMedCrossRef Guzmán-Medrano R, Arreola-Rosales RL, Shibayama M, Silva-Olivares DA, Bologna-Molina R, Rodríguez MA. Tumor-associated macrophages and angiogenesis: a statistical correlation that could reflect a critical relationship in ameloblastoma. Pathol Res Pract. 2012;208(11):672–6.PubMedCrossRef
13.
Zurück zum Zitat Sherlin HJ, Natesan A, Ram P, Ramani P, Thiruvenkadam C. Immunohistochemical profiling of ameloblastoma using cytokeratin, vimentin, smooth muscle actin, CD34 and S-100. Ann Maxillofac Surg. 2013;3(1):51–7.PubMedCentralPubMedCrossRef Sherlin HJ, Natesan A, Ram P, Ramani P, Thiruvenkadam C. Immunohistochemical profiling of ameloblastoma using cytokeratin, vimentin, smooth muscle actin, CD34 and S-100. Ann Maxillofac Surg. 2013;3(1):51–7.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Nouaem MI. Association between vascular endothelial growth factor (VEGF) expression and tumor angiogenesis in benign and malignant ameloblastoma. Egypt Dent J. 2005;51(17):186. Nouaem MI. Association between vascular endothelial growth factor (VEGF) expression and tumor angiogenesis in benign and malignant ameloblastoma. Egypt Dent J. 2005;51(17):186.
15.
Zurück zum Zitat Waldron CA, El-Mofty SK. A histopathologic study of 116 ameloblastomas with special reference to the desmoplastic variant. Oral Surg Oral Med Oral Pathol. 1987;63(4):441–51.PubMedCrossRef Waldron CA, El-Mofty SK. A histopathologic study of 116 ameloblastomas with special reference to the desmoplastic variant. Oral Surg Oral Med Oral Pathol. 1987;63(4):441–51.PubMedCrossRef
16.
Zurück zum Zitat Adebiyi KE, Ugboko VI, Omoniyi-Esan GO, Ndukwe KC, Oginni FO. Clinicopathological analysis of histological variants of ameloblastoma in a suburban Nigerian population. Head Face Med. 2006;2:42.PubMedCentralPubMedCrossRef Adebiyi KE, Ugboko VI, Omoniyi-Esan GO, Ndukwe KC, Oginni FO. Clinicopathological analysis of histological variants of ameloblastoma in a suburban Nigerian population. Head Face Med. 2006;2:42.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Tete S, Mastrangelo F, Grimaldi S, et al. Immunohistochemical evaluation of CD31 in human cystic radicular lesions and in keratocyst. Int J Immunopathol Pharmacol. 2005;18:39–45.PubMed Tete S, Mastrangelo F, Grimaldi S, et al. Immunohistochemical evaluation of CD31 in human cystic radicular lesions and in keratocyst. Int J Immunopathol Pharmacol. 2005;18:39–45.PubMed
18.
Zurück zum Zitat Bailey CM, Khalkhali-Ellis Z, Seftor EA, Hendrix MJ. Biological functions of maspin. J Cell Physiol. 2006;209:617–24.PubMedCrossRef Bailey CM, Khalkhali-Ellis Z, Seftor EA, Hendrix MJ. Biological functions of maspin. J Cell Physiol. 2006;209:617–24.PubMedCrossRef
19.
Zurück zum Zitat Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ, Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci U S A. 1996;93:11669–74.PubMedCentralPubMedCrossRef Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ, Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci U S A. 1996;93:11669–74.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Kumamoto H, Ooya K. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors. J Oral Pathol Med. 2000;36(8):488–94.CrossRef Kumamoto H, Ooya K. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors. J Oral Pathol Med. 2000;36(8):488–94.CrossRef
21.
Zurück zum Zitat Sijana HD, Alexander K, Xiaohua L, Margarida B, Yonghong M, Ivory D, et al. Identification of an intrinsic determinant critical for maspin subcellular localization and function. PLoS One. 2013;8(11):e74502.CrossRef Sijana HD, Alexander K, Xiaohua L, Margarida B, Yonghong M, Ivory D, et al. Identification of an intrinsic determinant critical for maspin subcellular localization and function. PLoS One. 2013;8(11):e74502.CrossRef
Metadaten
Titel
Expression of CD34 and Maspin in ameloblastoma from a West African subpopulation
verfasst von
S. E. Udeabor
A. O. Adisa
B. Kolude
M. Barbeck
C. J. Kirkpatrick
R. A. Sader
S. Ghanaati
Publikationsdatum
01.08.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 8/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1977-y

Weitere Artikel der Ausgabe 8/2014

Tumor Biology 8/2014 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.